Å finne en kreftcelle – og bestemme dens opphav

AD autoimmune disorders, ALL acute lymphoblastic leukaemia, Allo allogeneic transplantation, AML acute myeloid leukaemia, Auto autologous transplantation, CML chronic

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute

Phase I/II study of volasertib (BI 6727), an intravenous polo-like kinase (Plk) inhibitor, in patients with acute myeloid leukemia (AML): updated results of the dose fi nding phase

Because of the potential sensitizing effect of VPA by HK1knockdown in MOLM13 and HPRT1 knockdown in HL60, this might suggests that the reduced protein

Valproic acid (VPA) is a HDAC inhibitor that has been investigated in several clinical AML studies, usually in combination with all-trans retinoic acid (ATRA) for treatment of

The indication that S-phase arrest is important to establish the synergistic effect of combination therapy is emphasized when cell cycle status of OCI-AML3 cells is followed over

Valproic acid in combination with all-trans retinoic acid and intensive induction therapy for acute myeloid leukemia in older patients. Mechanism of action of

Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with